The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Structural variation is a key driver of relapse and aggressive clinical behavior in multiple myeloma
Although they play a role in resistance to treatment, very few single nucleotide variants (SNVs) and insertions/deletions (InDels) are drivers of the progression of multiple myeloma (MM). Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, discusses structural variation, identified by whole-genome sequencing (WGS), and highlights that complex structural variants deregulate multiple genes simultaneously, providing a novel mechanism driving relapse and disease progression in myeloma. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Janssen Pharmaceuticals
